# Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC

> **NCT03075423** · PHASE2 · COMPLETED · sponsor: **Goethe University** · enrollment: 316 (actual)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Ipilimumab plus nivolumab
- **DRUG:** Standard Therapy

## Key facts

- **NCT ID:** NCT03075423
- **Lead sponsor:** Goethe University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-01
- **Primary completion:** 2023-11-23
- **Final completion:** 2023-11-23
- **Target enrollment:** 316 (ACTUAL)
- **Last updated:** 2025-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03075423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03075423, "Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03075423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*